Clinical Prevalences of Antifbrotic Therapy for ILD- A Prospective Study
Not Applicable
Recruiting
- Conditions
- Interstitial Lung Disease
- Registration Number
- JPRN-UMIN000039664
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
Malignancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS)
- Secondary Outcome Measures
Name Time Method 1) Overall Survival 2) CT finding, Symptom, Incidences of Acute Exacerbation and Lung Cancer 3) Pulmonary Function Test (%FVC) 4) Explore biomarker
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antifibrotic therapy effectiveness in interstitial lung disease (ILD)?
How does JPRN-UMIN000039664 compare antifibrotic agents to standard-of-care treatments for ILD subtypes?
Which biomarkers correlate with response to antifibrotic therapies in ILD patients enrolled in JPRN-UMIN000039664?
What adverse events are associated with antifibrotic drugs in ILD observational studies like JPRN-UMIN000039664?
Are there combination therapies or alternative drugs being evaluated alongside antifibrotic agents for ILD?